Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰生物制药股份有限公司董事、高级管理人员和核心技术人员所持本公司股份及其变动管理办法 | 2025-08-20 | Chinese | |
| 百奥泰 2025年半年度募集资金存放、管理与实际使用情况的专项报告 | 2025-08-20 | Chinese | |
| 百奥泰 关于公司2025年度提质增效重回报专项行动方案的半年度评估报告 | 2025-08-20 | Chinese | |
| 百奥泰 关于与STADA就BAT1806（托珠单抗）注射液签署授权许可与商业化协议的公告 | 2025-08-20 | Chinese | |
| 百奥泰生物制药股份有限公司募集资金专项存储及使用管理制度 | 2025-08-20 | Chinese | |
| 百奥泰生物制药股份有限公司信息披露管理制度 | 2025-08-20 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 39230550 | 百奥泰生物制药股份有限公司董事、高级管理人员和核心技术人员所持本公司股份及其变动管理办法 | 2025-08-20 | Chinese | ||
| 39230537 | 百奥泰 2025年半年度募集资金存放、管理与实际使用情况的专项报告 | 2025-08-20 | Chinese | ||
| 39230527 | 百奥泰 关于公司2025年度提质增效重回报专项行动方案的半年度评估报告 | 2025-08-20 | Chinese | ||
| 39230517 | 百奥泰 关于与STADA就BAT1806（托珠单抗）注射液签署授权许可与商业化协议的公告 | 2025-08-20 | Chinese | ||
| 39230510 | 百奥泰生物制药股份有限公司募集资金专项存储及使用管理制度 | 2025-08-20 | Chinese | ||
| 39230503 | 百奥泰生物制药股份有限公司信息披露管理制度 | 2025-08-20 | Chinese | ||
| 39230497 | 百奥泰生物制药股份有限公司章程（2025年8月） | 2025-08-20 | Chinese | ||
| 39230479 | 百奥泰生物制药股份有限公司董事、高级管理人员薪酬管理制度 | 2025-08-20 | Chinese | ||
| 39230474 | 百奥泰 自愿披露关于调整BAT3306（帕博利珠单抗）开发策略的进展公告 | 2025-08-20 | Chinese | ||
| 39230464 | 百奥泰 股东减持股份结果公告 | 2025-08-19 | Chinese | ||
| 39230460 | 百奥泰 关于归还暂时用于补充流动资金的闲置募集资金的公告 | 2025-08-18 | Chinese | ||
| 39230450 | 百奥泰 自愿披露关于BAT1308注射液联合BAT4706注射液及注射用BAT8008治疗晚期实体瘤获得药物临床试验批准通知书的公告 | 2025-08-07 | Chinese | ||
| 39230448 | 百奥泰 自愿披露关于重组抗VEGF人源化单克隆抗体注射液（BAT5906）获得药物临床试验批准通知书的公告 | 2025-08-01 | Chinese | ||
| 39230443 | 百奥泰 关于变更办公地址和投资者联系方式的公告 | 2025-07-31 | Chinese | ||
| 39230436 | 百奥泰 2025年半年度业绩预告的自愿性披露公告 | 2025-07-29 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.